December 2025 to March 2026
Author: Cecile Philippoteaux
GLP-1 receptor agonists reduce vertebral fracture risk in patients with type 2 diabetes
Khor et al. assessed the association between GLP-1 receptor agonist (GLP-1 RA) use and vertebral fracture (VF) risk in patients with type 2 diabetes using the TriNetX database. After propensity score matching (n=193,563 pairs), GLP-1 RA use was associated with significantly lower odds of VF (incidence 1.5% vs 1.8%; OR 0.83 [95% CI 0.79–0.87]) and reduced need for vertebroplasty or kyphoplasty (OR 0.80 [95% CI 0.65–0.99]). These findings suggest a potential bone-protective role of GLP-1 RAs, possibly mediated through RANKL/OPG signaling and modulation of bone microarchitecture.
Higher RA disease activity doubles the risk of incident osteoporotic fractures: the VARA registry
Wysham et al. examined the relationship between disease activity and osteoporotic fracture in 2,912 veterans with rheumatoid arthritis from the multicenter VARA registry over 21,759 person-years. Each unit increase in time-varying DAS28-ESR conferred an 18% increased fracture risk (aHR 1.18 [95% CI 1.09–1.28]), while moderate and high disease activity categories carried approximately a 2-fold risk versus remission (aHR 2.24 and 2.01 respectively). Fractures affected predominantly the extremities (33%), ribs (24%), spine (20%), and hip (18%). Patient global assessment was the strongest individual predictor, underscoring the importance of treat-to-target strategies for fracture prevention.
Obinutuzumab superior to placebo in active systemic lupus erythematosus: the ALLEGORY phase 3 trial
Furie et al. conducted a phase 3, double-blind, placebo-controlled trial of obinutuzumab, a glycoengineered type II anti-CD20 monoclonal antibody, in 303 adults with active systemic lupus erythematosus (SLE) without proliferative lupus nephritis. At week 52, SLE Responder Index-4 (SRI-4) response was achieved in 76.7% of obinutuzumab-treated patients versus 53.5% with placebo (adjusted difference 23.1 percentage points; P<0.001). Obinutuzumab was superior on all key secondary endpoints including BILAG-based Composite Lupus Assessment (BICLA) response, sustained glucocorticoid reduction, and time to first flare, with a manageable safety profile.
Frailty independently increases fracture risk, partially mediated by inflammatory biomarkers: UK Biobank study
Zhang et al. investigated the association between frailty and incident fractures in 418,700 UK Biobank participants over a median follow-up of 13.6 years. Frailty was associated with a >50% increased risk of any fracture (HR 1.53), with the strongest effect observed for vertebral fractures (HR 2.33). Mediation analyses revealed that CRP, neutrophils, and platelets significantly mediated 0.86–2.20% of the frailty–fracture association, highlighting inflammation as a partial mechanistic pathway linking frailty to skeletal fragility.
Accelerated spine age estimated from DXA predicts fractures and mortality independently of BMD
Cho et al. applied a deep learning convolutional neuronal network (CNN) to DXA vertebral fracture assessment images from 8,810 adults in the Manitoba Bone Mineral Density (BMD) Registry to estimate “spine age“, a biological age derived from vertebral morphology that may differ from chronological age. Each standard deviation increase in predicted age difference (spine age minus chronological age) was independently associated with higher risks of any fracture (aHR 1.11), hip fracture (aHR 1.25), and mortality (aHR 1.12), after adjustment for age, BMD, vertebral fractures, and other covariates. This imaging-derived biological age biomarker may enhance fracture risk stratification beyond conventional tools.
Cécile Philippoteaux
Cécile Philippoteaux is a physician and clinical fellow in the Rheumatology Department at Lille University Hospital, France. Her clinical and research interests primarily focus on bone diseases, including secondary osteoporosis, rare and constitutional bone disorders, and the use of real-world data for outcomes research. She is currently pursuing a PhD in medical informatics and epidemiology. Her work leverages the French nationwide health claims database to study pharmaco-epidemiological and prognostic aspects of bone diseases, such as drug-induced osteoporosis, fracture risk prediction, and comorbidity profiles in rare skeletal disorders. Cécile is an active member of the young division working group of the French Society of Rheumatology (SFR) and a member of the EMEUNET Newsletter Sub-Committee.